PROPHYLAXIS AND THERAPY OF BRONCHOPULMONARY DYSPLASIA: WHAT IS THE BASE OF EVIDENCE OF EFFECTIVENESS?


D.Yu. Ovsyannikov, MD, A.M. Bolibok

Peoples' Friendship University of Russia, Moscow
Improvement of methods for nursing of infants with very low and extremely low birth weight leads to an increase in their survival and the emergence of a growing number of children with bronchopulmonary dysplasia. The article presents the current recommendations for the prevention and treatment of bronchopulmonary dysplasia based on the results of randomized clinical trials.

Literature


  1. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer N.N., Carlo W.A., Walsh M.C., Rich W., Gantz M.G., Laptook A.R., Yoder B.A., Faix R.G., Das A., Poole W.K., Donovan E.F., Newman N.S., Ambalavanan N., Frantz I.D. 3rd, Buchter S., Sanchez P.J., Kennedy K.A., Laroia N., Poindex-ter B.B., Cotten C.M., Van Meurs K.P., Duara S., Narendran V., Sood B.G., O’Shea T.M., Bell E.F., Bhandari V., Watterberg K.L., Higgins R.D. Early CPAP versus surfactant in extremely preterm infants. N. Engl. J. Med. 2010;362:1970–79.
  2. Sandri F., Plavka R., Ancora G., Simeoni U., Stranak Z., Martinelli S., Mosca F., Nona J., Thomson M., Verder H., Fabbri L., Halliday H.; CURPAP Study Group. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics. 2010;125:e1402–09.
  3. Rojas-Reyes M.X., Morley C.J., Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst. Rev. 2012:CD000510.
  4. Stevens T.P., Harrington E.W., Blennow M., Soll R.F. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst. Rev. 2007:CD003063.
  5. Verder H., Robertson B., Greisen G., Ebbe-sen F., Albertsen P., Lundstrom K., Jacobsen T. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N. Engl. J. Med. 1994;331:1051–55.
  6. Sweet D.G., Carnielli V., Greisen G., Hallman M., Ozek E., Plavka R., Saugstad O.D., Simeoni U., Speer C.P., Vento M., Halliday H.L.; European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants – 2013 update. Neonatology. 2013;103:353–68.
  7. Morley C.J. Volume-limited and volumetargeted ventilation. Clin. Perinatol. 2012;39:513–23.
  8. Wheeler K., Klingenberg C., McCallion N., Morley C.J., Davis P.G. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst. Rev. 2010:CD003666.
  9. Erickson S.J., Grauaug A., Gurrin L., Swaminathan M. Hypocarbia in the ventilated preterm infant and its effect on intraventricular haemorrhage and bronchopulmonary dysplasia J. Paediatr. Child. Health. 2002;38:560–62.
  10. The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity, a randomized, controlled trial. Pediatrics. 2000;105:295–310.
  11. Askie L.M., Henderson-Smart D.J., Irwig L., Simpson J.M. Oxygen saturation targets and outcomes in extremely preterm infants. N. Engl. J. Med. 2003;349:959–67.
  12. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo W.A., Finer N.N., Walsh M.C. , Rich W., Gantz M.G., Laptook A.R., Yoder B.A., Faix R.G., Das A., Poole W.K., Schibler K., Newman N.S., Ambalavanan N., Frantz I.D. 3rd, Piazza A.J., Sanchez P.J., Morris B.H., Laroia N., Phelps D.L., Poindexter B.B., Cotten C.M., Van Meurs K.P., Duara S., Narendran V., Sood B.G., O’Shea T.M., Bell E.F., Ehrenkranz R.A., Watterberg K.L., Higgins R.D. Target ranges of oxygen saturation in extremely preterm infants. N. Engl. J. Med. 2010;362:1959–69.
  13. Stenson B., Brocklehurst P., Tarnow-Mordi W. Increased 36-week survival with high oxygen saturation target in extremely preterm infants N. Engl. J. Med. 2011;364:1680–82.
  14. Galie N., Hoeper M., Humbert M. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2009;30(20):2493–537.
  15. Abman S.H. Approach to the child with pulmonary hypertension and bronchopulmonary dysplasia. Advances Pulm. Hypertens. 2011;10(2):98–103.
  16. Allen J., Zwerdling R., Ehrenkranz R., Gaultier C., Geggel R., Greenough A., Kleinman R., Klijanowicz A., Martinez F., Ozdemir A., Panitch H.B., Nickerson B., Stein M.T., Tomezsko J., van der Anker J.; American Thoracic Society.Statement on the care of the child with chronic lung disease of infancy and childhood. Am. J. Respir. Crit. Care Med. 2003;168:356–96.
  17. Nievas F.F., Chernick V. Bronchopulmonary dysplasia: an update for the pediatrician. Clin. Pediatr. 2002;41:77–85.
  18. Подготовка больных с респираторной патологией к авиаперелетам. Рекомендации Британского торакального общества. Пульмонология. 2005;5:13–34.
  19. Schmidt B., Roberts R.S., Davis P., Doyle L.W., Barrington K.J., Ohlsson A., Solimano A., Tin W.; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity N. Engl. J. Med. 2006;354:2112–21.
  20. Henderson-Smart D.J., Davis P.G. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst. Rev. 2010:CD000139.
  21. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2010:CD001146.
  22. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2009:CD001145.
  23. Doyle L.W., Halliday H.L., Ehrenkranz R.A., Davis P.G., Sinclair J.C. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease Pediatrics. 2005;115:655–61.
  24. Бабак О.А., Воронцова Ю.Н., Геппе Н.А. и др. Бронхолегочная дисплазия. Методические рекомендации / Под ред. акад. РАМН Н.Н. Володина. М., 2010. 56 c.
  25. Doyle L.W., Davis P.G., Morley C.J., McPhee A., Carlin J.B.; DART Study Investigators. Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial. Pediatrics. 2006;117:75–83.
  26. Onland W., Offringa M., Jaegere A.P. De, van Kaam A.H. Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled Trials. Pediatrics. 2009;123(1):367–77.
  27. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114:1649–57.
  28. Ng G.Y.T., da Silva O., Ohlsson A. Bronchodila-tion for the prevention and treatment of chro-nic lung disease in preterm infants. Cochrane Database Syst. Rev. 2001;23:CD003214.
  29. Yuksel B., Greenough A., Maconachie I. Effective bronchodilator therapy by a simple spacer device for wheezy premature infants in the first two years of life. Arch. Dis. Child. 1990;65: 782–85.
  30. Wilkie R.A., Bryan M.H. Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J. Pediatr. 1987;111(2):278–82.
  31. Володин Н.Н. Актуальные проблемы неонатологии. М., 2004. C. 177–90.
  32. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118:1774–93.
  33. Schweich P.J., Hurt T.L., Walkley E.I., Mullen N., Archibald L.F. The use of nebulized albute-rol in wheezing infants. Pediatr. Emerg. Care. 1992;8:184–88.
  34. Schuh S., Canny G., Reisman J.J., Kerem E., Bentur L., Petric M., Levison H. Nebulized albuterol in acute bronchiolitis. J. Pediatr. 1990;117:633–37.
  35. Shah S.S., Ohlsson A., Halliday H., Shah V.S. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane review in The Cochrane Library. 2003;Issue 3. http://www.nichd.nih.gov/cochraneneonatal/Shah8/Shah.htm
  36. Shah V.S., Ohlsson A., Halliday H.L., Dunn M.S. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane review in The Cochrane Library 2003;Issue 3. http://www.nichd.nih.gov/cochraneneonatal/shah2/Shah.htm
  37. Dugas M.A., Nguyen D., Frenette L., Lachance C., St-Onge O., Fougeres A., Belanger S., Caouette G., Proulx E., Racine M.C., Piedboeuf B. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediarics. 2005;115:566–72.
  38. Pantalitschka T., Poets C.F. Inhaled drugs for the prevent and treatment of bronchopulmonary dysplasia. Pediatr. Pulmonol. 2006;41:703–08.
  39. Овсянников Д.Ю., Дегтярева Е.А. Клинико-фармакоэкономический анализ терапии бронхолегочной дисплазии у детей первых трех лет жизни. Российский педиатрический журнал. 2008;4:10–6.
  40. Давыдова И.В. Формирование, течение и исходы бронхолегочной дисплазии у детей. Дисс. докт. мед. наук. М., 2010. 48 с.
  41. Pandit P.B., Dunn M.S., Kelly E.N., Perlman M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics. 1995;95:851–54.
  42. Checchia P.A., Nalysnyk L., Fernandes A.W., Mahadevia P.J., Yingxin Xu, Fahrbach K., Welli-ver R.C. Mortality and and morbidity among infants at high risk for severe respiratory syncytial virus infection receving prophilaxis with palivizumab: A systematic literature review and meta-analysis. Pediatr. Crit. Care Med. 2011;12(5):580–88.
  43. Игнатьева В.И., Авксентьева М.В., Реброва О.Ю. и др. Клинико-экономический анализ результатов программы иммунопрофилактики РСВ-инфекции в эпидемический сезон 2012/2013 в Москве. Педиатрическая фармакология. 2013;10(6):17–26.


About the Autors


D.Yu. Ovsyannikov - MD, Head. of the Department of Pediatrics, Peoples' Friendship University of Russia


Similar Articles


Бионика Медиа